Recently, there are a variety of clinical trials focusing on BRCA1 as a biomarker to provide prognostic information in NSCLC, but conflicting data requires further prospective validation and patient validation in clinical trials, also suggesting the importance of epigenetic BRCA1 expression [23–25]. Here, BRCA1 is linked to non-small cell lung carcinoma.